Print

Hereditary Antithrombin Deficiency and rEVO Biologics’ ATryn to Appear on January 28th TV segment on Lifetime Morning Show, The Balancing Act™  
1/24/2013 9:34:41 AM

FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics announced today that hereditary antithrombin (AT) deficiency, and the use of the company’s lead product ATryn antithrombin (Recombinant), will be the focus of a TV segment on Behind the Mystery: Rare and Genetic Diseases, the ground breaking series on The Balancing Act™, America’s premier morning show that airs weekday mornings on Lifetime Television.
//-->